Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market (Drug Class - Bronchodilators, Combination, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids, and Other Drug Class; Distribution Channel - Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

  • Published : May, 2019

  • Rep Id : HC0504

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on chronic obstructive pulmonary disease (COPD) therapeutics market provides an in-depth analysis of segments and sub-segments in the global as well as regional chronic obstructive pulmonary disease therapeutics market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional chronic obstructive pulmonary disease therapeutics market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global chronic obstructive pulmonary disease therapeutics market. According to the report, the global chronic obstructive pulmonary disease therapeutics market is projected to grow at a healthy CAGR over the forecast period of 2019-2025.

 

Market Insight

Chronic obstructive pulmonary disease is a chronic inflammatory lung disease that causes obstructive airflow from the lungs. COPD is caused by prolonged exposure to polluted or irritating gases and particulate matter. COPD can result in severe heart disease, lung cancer, and other disorders. Emphysema and chronic bronchitis are two common conditions that contribute to COPD. Emphysema can be caused by longer exposure to cigarette smoke and other irritating gases and particulate matter. Chronic bronchitis is an inflammation of the lining of the bronchial tubes, which carry air to and from the air sacs (alveoli) of the lungs. Some of the common symptoms of COPD include increased shortness of breath, frequent coughing (with and without mucus), increased breathlessness, wheezing and tightness in the chest. COPD is not curable yet, but with proper management, a person can achieve good symptom control and quality of life.


The most prominent factor affecting the growth of the chronic obstructive pulmonary disease therapeutics market is a persistent rise in the number of COPD cases globally. WHO report states the prevalence of 251 million cases of COPD globally in 2016, and it is estimated that 3.17 million deaths were caused by the disease in 2015, which is 5% of all deaths globally in the year. Another factor supporting the growth of the market is changing life habits, increasing the number of tobacco smokers, and prolong exposure to polluted air environments are responsible for raising the number of chronic obstructive pulmonary disease patients. However, lack of knowledge and awareness regarding COPD indication and symptoms, lack of precision in the diagnosis of the disease are some major drawbacks contributing to the slow growth of the market. On the other hand, strong pipeline drugs and rising government initiatives will provide better opportunities for the COPD market.


Geographically, North America dominates the market and continue to stay on top in the forecast year. An increasing number of tobacco smokers, advanced diagnosis facilities, and raising awareness among people are some factors affecting the growth of this region. The market in Europe for COPD will grow with a healthy rate in the near future owing to heavy spending on R&D and the introduction of new products into the market. Asia-Pacific region will grow with a lucrative rate in the forecast period, increasing the prevalence of COPD, increasing air pollution level, and growing pharmaceutical industries will aid the growth of the market.


Global Chronic Obstructive Pulmonary Disease Therapeutics Market

 

Segment Covered

The report on global chronic obstructive pulmonary disease therapeutics market covers segments such as drug class, and distribution channel. On the basis of drug class, the sub-markets include bronchodilators, combination, phosphodiesterase type 4 inhibitors, mucokinetics, corticosteroids, and other drug class. On the basis of distribution channel, the sub-markets include online pharmacies, hospital pharmacies, and retail pharmacies.

 

Companies Profiled:

The report provides profiles of the companies in the market such as Pfizer Inc., Adamis Laboratories, Inc., AstraZeneca Plc, Boehringer Ingelheim Pharmaceuticals, Inc., Novartis AG, and Sunovion Pharmaceuticals, Inc.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of chronic obstructive pulmonary disease therapeutics market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount